CDMOs Play a Critical Role in the Biopharmaceutical Ecosystem

Hideyuki Kurata; Tetsuya Ishino; Yasuhiro Ohshima; Masafumi Yohda

doi:10.3389/fbioe.2022.841420

CDMOs Play a Critical Role in the Biopharmaceutical Ecosystem

Front Bioeng Biotechnol. 2022 Mar 21:10:841420. doi: 10.3389/fbioe.2022.841420. eCollection 2022.

Authors

Hideyuki Kurata^{1

2}, Tetsuya Ishino^{1

3}, Yasuhiro Ohshima⁴, Masafumi Yohda²

Affiliations

¹ Technology General Division, AGC Inc., Tokyo, Japan.
² Institute of Engineering, Tokyo University of Agriculture and Technology, Tokyo, Japan.
³ AGC Biologics, Bothell, WA, United States.
⁴ Business Development Division, AGC Inc., Tokyo, Japan.

Abstract

Biopharmaceutical industries have advanced significantly after the millennium. Novel biopharmaceuticals have been developed one after another, and blockbuster drugs have been produced. Accompanying the increase in the demand for biopharmaceuticals, a business model called "contract development manufacturing organization (CDMO)" has emerged. A CDMO is entrusted with the development and manufacturing of production processes from pharmaceutical companies. In this review, we identify the success factors of the biopharmaceutical CDMO by analyzing the foundry business for the semiconductor industry. Furthermore, we also review monoclonal antibody production platforms and new technologies that are critical aspects of differentiation strategies in the biopharmaceutical CDMO.

Keywords: CDMO; biologics; bioprocess; foundry; monoclonal antibody; semiconductor.

Publication types

Review